TY - JOUR
T1 - The state of Melanoma
T2 - Emergent challenges and opportunities
AU - Melanoma Research Foundation
AU - Atkins, Michael B.
AU - Curiel-Lewandrowski, Clara
AU - Fisher, David E.
AU - Swetter, Susan M.
AU - Tsao, Hensin
AU - Aguirre-Ghiso, Julio A.
AU - Soengas, Maria S.
AU - Weeraratna, Ashani T.
AU - Flaherty, Keith T.
AU - Herlyn, Meenhard
AU - Sosman, Jeffrey A.
AU - Tawbi, Hussein A.
AU - Pavlick, Anna C.
AU - Cassidy, Pamela B.
AU - Chandra, Sunandana
AU - Chapman, Paul B.
AU - Daud, Adil
AU - Eroglu, Zeynep
AU - Ferris, Laura K.
AU - Fox, Bernard A.
AU - Gershenwald, Jeffrey E.
AU - Gibney, Geoffrey T.
AU - Grossman, Douglas
AU - Hanks, Brent A.
AU - Hanniford, Douglas
AU - Hernando, Eva
AU - Jeter, Joanne M.
AU - Johnson, Douglas B.
AU - Khleif, Samir N.
AU - Kirkwood, John M.
AU - Leachman, Sancy A.
AU - Mays, Darren
AU - Nelson, Kelly C.
AU - Sondak, Vernon K.
AU - Sullivan, Ryan J.
AU - Merlino, Glenn
N1 - Publisher Copyright:
© American Association for Cancer Research.
PY - 2021/5
Y1 - 2021/5
N2 - Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has been made on both the basic and clinical research fronts. However, the incidence, recurrence, and death rates for melanoma remain unacceptably high and significant challenges remain. Hence, the MRF Scientific Advisory Council and Breakthrough Consortium, a group that includes clinicians and scientists, reconvened to facilitate intensive discussions on thematic areas essential to melanoma researchers and patients alike, prevention, detection, diagnosis, metastatic dormancy and progression, response and resistance to targeted and immune-based therapy, and the clinical consequences of COVID-19 for patients with melanoma and providers. These extensive discussions helped to crystalize our understanding of the challenges and opportunities facing the broader melanoma community today. In this report, we discuss the progress made since the last MRF assessment, comment on what remains to be overcome, and offer recommendations for the best path forward.
AB - Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has been made on both the basic and clinical research fronts. However, the incidence, recurrence, and death rates for melanoma remain unacceptably high and significant challenges remain. Hence, the MRF Scientific Advisory Council and Breakthrough Consortium, a group that includes clinicians and scientists, reconvened to facilitate intensive discussions on thematic areas essential to melanoma researchers and patients alike, prevention, detection, diagnosis, metastatic dormancy and progression, response and resistance to targeted and immune-based therapy, and the clinical consequences of COVID-19 for patients with melanoma and providers. These extensive discussions helped to crystalize our understanding of the challenges and opportunities facing the broader melanoma community today. In this report, we discuss the progress made since the last MRF assessment, comment on what remains to be overcome, and offer recommendations for the best path forward.
UR - http://www.scopus.com/inward/record.url?scp=85106306069&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106306069&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-20-4092
DO - 10.1158/1078-0432.CCR-20-4092
M3 - Article
C2 - 33414132
AN - SCOPUS:85106306069
SN - 1078-0432
VL - 27
SP - 2678
EP - 2697
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -